Loading…
← CockpitCompetitor Analysis › 688382.SS InventisBio, Co., Ltd. Class AOpen in the cockpit ↗

InventisBio, Co., Ltd. Class A688382.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shanghai clinical-stage biotech developing small-molecule drugs for cancer and inflammatory diseases, largely pre-revenue.

≈ A small, China-based clinical biotechMomentum laggard 3
Mkt cap
$982M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$39.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.7%
Hurdle
+67 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥11.47
1D-2.0%
1W-17.4%
1M-25.3%
3M-45.9%
6M-46.7%
YTD-57.9%
1Y-60.2%
ATR %8.0%
52w lowhigh66.8% off high

What InventisBio does

Shanghai clinical-stage biotech developing small-molecule drugs for cancer and inflammatory diseases, largely pre-revenue.

In one line: A small, China-based clinical biotech.

Products and services

  • Oncology drug candidates
  • Inflammation/autoimmune drug candidates

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech
  • Oncology and inflammation small…

What could go right

  • Clinical trial data readouts
  • Licensing deals with global pharma

What could go wrong

  • Trial failure risk
  • Cash burn before approval

Moat: none (IP / patents). Pipeline value depends on trial results and patents, not yet a commercial franchise.

Headquarters: Shanghai, China · Employees: 182

Named competitors

InventisBio at a glance

Size InventisBio (688382.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $982M, the 2186th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.47 on 18 Nov 2026.

Performance Over six months the shares fell 46.7%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 60.6% over the last twelve months (peer median +9.8%); the operating margin is -562.8% (peer median 12.6%).

Valuation It trades at 75.0× enterprise value to sales against a peer median of 2.7× (most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -61%, so the hurdle is +67 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 92688382.SS 57
Six months, rebased to 100: InventisBio against the median of its 20 peers (local-currency closes).

InventisBio financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥71.1MCN¥37.3MCN¥169MCN¥186MCN¥0
Revenue growth—-78%-9%——
Gross profitCN¥66.2MCN¥16.1MCN¥145MCN¥163M-CN¥19.9M
EBITDAn/a-CN¥335M-CN¥261M-CN¥305M-CN¥500M
Net income-CN¥379M-CN¥317M-CN¥240M-CN¥284M-CN¥483M
Free cash flowCN¥371M-CN¥146M-CN¥228M-CN¥307M-CN¥485M
Capital expenditureCN¥7.50MCN¥6.92MCN¥7.56MCN¥6.29MCN¥7.69M
Total debtCN¥17.5MCN¥22.1MCN¥23.9MCN¥11.6MCN¥27.3M

Quarterly statements and history in the cockpit →

InventisBio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%600129AARTIPHARMSPTXPGHL600557456568871060511668809168875930029448873007022005603538300497002437600422688382.SS6-month return →1-month return →
Up and to the right = strong over both horizons. InventisBio is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×25×50×75×600129AARTIPHARMPGHL600557688091300294300702300497002437600422688382.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InventisBio is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%PGHL60055745656887106051160006502005STAR603538300497688382.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InventisBio is the large dot.

InventisBio competitors and peer comparison

Head to head with its named competitors (688382.SS vs 600276.SS vs 688235.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
InventisBio 688382.SS$982M-47%-61%-563%75.0×6.5%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
BeOne Medicines 688235.SS$45.5B+9%+25%18%6.3×19.1%

How InventisBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InventisBio against its 20 peers (data as of 18 Nov 2026)
Measure688382.SSPeer medianRank in peer set
1-month return-25.3%-6.5%lowest of 21
6-month return-46.7%-10.6%4th lowest of 21
Distance from 52-week high-66.8%-33.9%2nd lowest of 21
Revenue growth (TTM)-60.6%+9.8%lowest of 19
Operating margin-562.8%12.6%lowest of 19
EV / Sales75.0×2.7×most expensive of 19
Growth the price implies (Req g, 7 yrs)6.5%6.6%7th least demanding of 13
Growth delivered (Del g)-60.6%+4.2%lowest of 13
Hurdle (Req g minus delivered)+67.1 pp+0.6 ppmost demanding of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
InventisBio 688382.SSChina$982M-47%-61%-563%75.0×6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%1.3×n/an/a
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%4.7×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%1.4×2.3%+1.8%
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%1.3×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%0.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%2.3×4.3%+3.5%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%4.0×7.5%-4.5%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a

Questions

Who are InventisBio's main competitors?
Named competitors: Hengrui Medicine (600276.SS), BeiGene (688235.SS). The cockpit's measured peer set (industry) also includes Chongqing Taiji Industry (Group) (600129.SS), Aarti Pharmalabs (AARTIPHARM.NS), Seaport Therapeutics (SPTX), Procter & Gamble Health (PGHL.NS), Jiangsu Kanion Pharmaceutical (600557.SS), Nxera Pharma (4565.T).
Is InventisBio expensive compared with its peers?
On ev / sales it trades at 75.0× against a peer median of 2.7×, most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -61%, so the hurdle is +67 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has InventisBio stock performed?
Over six months to 18 Nov 2026 the shares returned -46.7% against -10.6% for the median peer; over one year -60.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.